Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

As of Friday, July 17, Mesoblast Limited’s MESO share price has dipped by 6.49%, which has investors questioning if this is ...

Mesoblast Limited ( (AU:MSB) ) has issued an announcement.

Welcome to this week’s HotCopper Highlights, where we look at the most viewed and most discussed stocks on the HotCopper ...

Recently published Degenerative Disc Disease Market Insights report includes a comprehensive understanding of current ...

Learn More Mesoblast Ltd (ASX: MSB) shares could be seriously undervalued. That's the view of the team at Bell Potter, which ...

An update from Mesoblast Limited ( (AU:MSB)) is now available. Mesoblast has received a U.S. FDA Biologics License Application filing number and requested modular review for rexlemestrocel‑L, an ...

Mesoblast recently reported half-year 2026 results showing revenue of US$51.34 million versus US$3.16 million a year earlier, with net loss narrowing to US$40.16 million, and issued full‑year 2026 ...

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a ...

Mesoblast focuses on allogeneic cellular medicines to treat inflammatory diseases. On Friday, the company said that it had received a Complete Response Letter (CRL) from the Food and Drug ...

NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate ...